On August 28, 2018 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, reported that it will present a corporate overview at the 2018 Wells Fargo 13th Annual Healthcare Conference, being held on September 5-6 in Boston, MA (Press release, Aeglea BioTherapeutics, AUG 28, 2018, View Source [SID1234529097]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo Healthcare Conference

Aeglea BioTherapeutics Presentation Details

Date: Wednesday, September 5

Time: 10:50 am Eastern Time

Location: The Westin Copley Place, Boston, MA

Webcast: https://cc.talkpoint.com/well001/090518a_as/?entity=51_HGGS50C
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.

Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aeglea’s Compensation Committee of its Board of Directors has granted non-qualified stock options to purchase an aggregate of 41,000 shares of Aeglea’s common stock to four new employees under Aeglea’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aeglea (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Aeglea, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The options have an exercise price of $10.28 or $10.54 per share, which is equal to the closing price of Aeglea’s common stock on August 24, 2018 or August 27, 2018, respectively. Each of the option awards vests as to 25% of the shares on the one-year anniversary of its grant, with the remainder of the shares vesting ratably over 36 months thereafter.

On August 28, 2018 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported that the Company will present on three panels at the B. Riley FBR Annual Healthcare Conference to be held on September 4, 2018 in New York City, as well as meeting with investors (Press release, Cellular Biomedicine Group, AUG 28, 2018, View Source [SID1234529160]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panels will range in topics from the latest development in CAR-T Cell Therapies to the role Chinese capital can play to fund innovation.

On August 28, 2018 Medtronic plc (NYSE:MDT), the global leader in medical technology, reported that it will participate in the 13th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 6, 2018, in Boston (Press release, Medtronic, AUG 28, 2018, View Source;p=RssLanding&cat=news&id=2365106 [SID1234529341]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bob White, executive vice president and president of the Minimally Invasive Therapies Group (MITG) of Medtronic, will answer questions about the company beginning at 10:55 a.m. EDT (9:55 a.m. CDT).

A live audio webcast of the presentation will be available on September 6, 2018, by clicking on the Investor Events link at View Source, and an archive of the session will be available on the same webpage later in the day.

On August 28, 2018 RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform reported that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, RXi Pharmaceuticals, AUG 28, 2018, View Source [SID1234529098]). The conference is being held September 4-6, 2018 at the St. Regis New York Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Gerrit Dispersyn, Chief Development Officer for the Company, will provide an overview of RXi’s business and ongoing programs for the development of RNAi-based immuno-oncology therapeutics that aim to fill the unmet need of other therapeutic approaches and, its strategy to tackle different immune escape mechanisms to treat cancer.

Date: Wednesday, September 5, 2018
Time: 3:25 p.m. Eastern Time
Location: Library, 2nd floor at the St. Regis New York Hotel in New York City
Webcast link: View Source

About this Conference

If you are an institutional investor and would like to attend RXi’s presentation, please click on the following link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with RXi.

About Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)

Immunotherapy of cancer has become increasingly important in clinical practice over the recent decade. By activating the patient’s immune system, immunotherapy treatments have shown remarkable promise in extending the lifespan of previously untreatable cancer patients. Adoptive cell therapy is an emerging immunotherapy approach which uses immune cells, such as T-lymphocytes or NK cells that are isolated from the patient or retrieved from allogeneic immune cell banks, and then expanded and in some cases processed to express tumor-binding receptors.

A new and important step in this ex-vivo processing of the immune cells is in development where self-delivering RNAi compounds (sd-rxRNA) are used to eliminate the expression of immunosuppressive receptors or proteins from the therapeutic immune cells, thereby making them less sensitive to tumor resistance mechanisms and improving their ability to destroy tumor cells. In this way, sd-rxRNA therapeutic compounds can be used to weaponize therapeutic immune cells to attack cancer and ultimately provide patients battling terminal cancers with a powerful new treatment option that goes beyond current treatment modalities.

On August 28, 2018 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported that Adelene Perkins, Infinity Pharmaceuticals’ Chief Executive Officer, and Lawrence Bloch, Infinity Pharmaceuticals’ President, will present at the following conferences (Press release, Infinity Pharmaceuticals, AUG 28, 2018, View Source [SID1234529119]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 20th Annual Global Investment Conferencein New York, NY on Wednesday September 5, 2018 at 1:45 p.m. ET

Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on Thursday, September 6, 2018 at 1:55 p.m. ET

25th Annual BioCentury NewsMakers in the Biotech Industry in New York, NY on Friday, September 7, 2018 at 8:30 a.m. ET. Additionally, for those who will be attending BioCentury NewsMakers, Adelene Perkins will be participating in the lunch panel from 12:15 – 1:15 p.m. ET on "Investing In Hot Topics Areas" moderated by Simone Fishburn, BioCentury’s VP and Executive Editor.

A live webcast of the presentation for each of these conferences, excluding the BioCentury NewsMakers lunch panel discussion, will be available on the Investors/Media section of Infinity’s website at www.infi.com, and will be available for 30 days following the event.